Fox, Elizabeth <br/><br/>
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2008 
 - 1111-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-4097  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Agents--administration & dosage<br/>Child<br/>Child, Preschool<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Maximum Tolerated Dose<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasms--drug therapy<br/>Sulfonamides--administration & dosage<br/>Tubulin Modulators--administration & dosage